IKCS 2019: Lenvatinib Plus Pembrolizumab in Subset of Patients With Kidney Cancer
Posted: Monday, December 2, 2019
According to findings presented at the 2019 International Kidney Cancer Symposium (IKCS) in Miami, lenvatinib plus pembrolizumab exhibited “promising” antitumor activity among patients with metastatic clear cell renal cell carcinoma who experienced disease progression during or after immune checkpoint inhibitor therapy. Chung-Han Lee, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, and colleagues, found that the combination of the multikinase VEGFR inhibitor and the anti–PD-1 antibody resulted in no new safety signals in this phase II study.
The investigators conducted a per-protocol interim analysis of a multicenter, open-label study for patients diagnosed with metastatic clear cell renal cell carcinoma. Patients had at least one prior therapy, demonstrated disease progression on or after immune checkpoint inhibition, had measurable disease, and exhibited an Eastern Cooperative Oncology Group performance status of at least 1. The investigators treated 33 patients with 20 mg/d of lenvatinib plus 200 mg of pembrolizumab intravenously every 3 weeks until disease progression or toxicity occurred.
At data cutoff, 24 patients (73%) were still on the study treatment. The authors observed an objective response rate of 52% and a disease control rate of 94%; most patients’ tumors displayed shrinkage. The median follow-up for progression-free survival was 4.2 months.
Among the study patients, the most common treatment-related adverse events were fatigue (49%), dysphonia (36%), diarrhea (33%), stomatitis (30%), hypertension (24%), dry mouth (21%), nausea (21%), proteinuria (21%), and hand-foot syndrome (21%). Three patients discontinued treatment due to adverse events.
Disclosure: For full disclosures of the study authors, visit www.kidneycancer.org.